Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Johnson and Johnson
Medtronic
Cipla

Generated: August 22, 2019

DrugPatentWatch Database Preview

Patent: 8,097,238

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,097,238
Title:Cell targeting conjugates
Abstract: The present invention relates to cell targeting conjugates and in particular, but not exclusively, to methods of their use in selectively eliminating and in selectively imaging target cells. The invention also relates to processes for production of the conjugates and to intermediate compounds that may be used in production of a specific class of cell targeting conjugates. In one embodiment there is provided a cell targeting conjugate comprising the following components that are covalently conjugated via a linker that is degradable within the target cells: i) a DNA minor groove binding ligand incorporating an effective Auger electron-emitting and/or gamma-emitting and/or positron-emitting atom or photoactive moiety; ii) a target cell specific protein or peptide that is capable of internalization by target cells.
Inventor(s): Martin; Roger Francis (Ivanhoe, AU), White; Jonathan Michael (Wheelers Hill, AU), Lobachevsky; Pavel Nikolaevich (Bulleen, AU), Karagiannis; Thomas Chris (Thornbury, AU)
Assignee: Peter MacCallum Cancer Institute (East Melbourne, AU)
Application Number:10/590,784
Patent Claims:see list of patent claims

Details for Patent 8,097,238

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Sign Up Peter MacCallum Cancer Institute (East Melbourne, AU) 2024-02-27 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Peter MacCallum Cancer Institute (East Melbourne, AU) 2024-02-27 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07 ➤ Sign Up Peter MacCallum Cancer Institute (East Melbourne, AU) 2024-02-27 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Sign Up Peter MacCallum Cancer Institute (East Melbourne, AU) 2024-02-27 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up Peter MacCallum Cancer Institute (East Melbourne, AU) 2024-02-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Chubb
Chinese Patent Office
Federal Trade Commission
Johnson and Johnson
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.